Although decoding the human genome through the invention of sequencing has ushered in a new era of biomedical sciences, this blueprint is not enough. We are defined by more than our genes: to understand the human body, we must understand the proteins that actually perform our day-to-day functions–and malfunctions. Proteins are a necessary building block of life. However, when proteins start to dysfunction, they can be leading cause of diseases. As such, understanding protein function and dysfunction is key to understanding human disease. Unfortunately, current protein technologies are heavily biased towards highly expressed proteins. As such, proteins with lower expression or novel, unknown proteins will not be accurately detected despite contributing to various pathologies. No technology exists that will identify all the proteins present, no matter the expression level, in healthy and diseased states. A platform that would do this will revolutionize our understanding of biology and more rapidly lead to relevant biological targets for targeted therapeutics.
Glyphic Biotechnologies has created that proteomics innovation.
We have developed a new way to sequence proteins at single molecule resolution. Glyphic Biotechnologies is decoding the human proteome through full coverage, de novo protein sequencing at single molecule resolutions, advancing beyond the decades old technologies based on mass spectrometry and ELISAs. We have integrated chemical and biological sensors to greatly increase signal-to-noise and provide a robust method of sequencing proteins at single molecule resolution. More specifically, we are developing a new technology that will allow us to identify proteins at the lowest concentration in biological samples for research and diagnostic purposes. This platform will enable the development of novel therapeutics and diagnostics and, ultimately, a deeper understanding of human biology.
A next-generation, single-molecule protein sequencing platform would usher in a new age of biomedical sciences, similar to how Illumina’s next-generation DNA sequencing machines marked an inflection point in our understanding of the genome. Our protein sequencing technology will be used by biopharma to drastically reduce the time and direct costs of discovering new biologic-based therapeutics and neoantigens, serving as a source of innovative product development. Researchers both in academia and industry would have access to a proteomics discovery workflow and tool that breaks free from the traditional throughput/cost curve that all other technologies in this space lie on. Far-reaching impacts would be seen in biopharmaceutical therapeutic discovery, rare disease diagnostics, clinical medicine, industrial biotechnology, and more.
Next generation protein sequencing has not yet been commercialized by any company. This is why our investors, who were the capital and resources behind the most innovative life science tool companies to date such as 10X Genomics, Seer, Twist Bioscience, Inscripta, and plenty more, believe that Glyphic Biotechnologies represents a revolution in the proteomics space with a technology that will usher in a new era of biomedical sciences and research, the same way that massively parallel DNA sequencing did based on Illumina/Solexa’s technologies. Our sequencing platform will be more than incremental–it will be transformative.
